Although the prevalence of species of the genus Acinetobacter other than Acinetobacter
baumannii has seemingly increased as a cause of nosocomial infections in different …

Clinical isolates of Acinetobacter baumannii complex (1312), Stenotrophomonas maltophilia
(464), and Burkholderia cepacia species complex (30) were selected from medical centers …

Objective: To investigate the in vitro and in vivo antibacterial activities of tigecycline and
other 13 common antimicrobial agents, alone or in combination, against multi-drug resistant …

Infections caused by Acinetobacter baumannii are difficult to treat as they are often multidrug
resistant (MDR) and frequently form biofilms. We investigated the activities of minocycline …

The emergence of colistin or tigecycline resistance as well as imipenem resistance in
Acinetobacter baumannii poses a great therapeutic challenge. The bactericidal and …

The optimal treatment for multidrug-resistant A. baumannii nosocomial infections has not
been established. Carbapenems are the mainstay of treatment in susceptible isolates …

Abstract Objectives Multidrug-resistant (MDR) Acinetobacter baumannii is increasing in our
hospital and worldwide, raising the necessity of finding effective therapies. We aimed to …

Background We investigated the presence of heteroresistance against both tigecycline and
colistin in Acinetobacter baumannii and then evaluated the effectiveness of combined …

Acinetobacter baumannii is an important nosocomial pathogen usually in the context of
serious underlying disease. Multidrug resistance in these organisms is frequent. The β …

As part of the Tigecycline Evaluation and Surveillance Trial, isolates of Escherichia coli,
Klebsiella pneumoniae, and Acinetobacter baumannii were collected in the United States …